Pipeline news

• binx health Announces Publication of Pivotal Study in JAMA Network Open

  14 May 2020

  

  binx health today announced the publication of its pivotal clinical study for its rapid molecular point-of-care platform, the binx io, in The Journal of the American Medical Association (JAMA) Network Open. The study shows that the binx io provides accurate results in about 30 minutes, enabling single visit test and treatment for chlamydia (CT) and gonorrhea (NG), two of the most tested-for sexually transmitted infections (STIs) globally. binx received FDA 510(k) clearance for its CT/NG Assay in August 2019 for female swabs and in April 2020 for male urine samples. The standard of care today for CT/NG testing often requires 2-10 days of delay between sample collection and answer, resulting up to 40% of positive patients not returning for treatment.

• Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update

  05 May 2020

  

  Syndax Pharmaceuticals, Inc.  (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended  March 31, 2020 . In addition, the Company provided a clinical and business update.

• Clearside Biomedical Announces First Quarter 2020 Financial Results

  05 May 2020

  

  Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for the first quarter ended  March 31, 2020 .

• Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results

  04 May 2020

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided an update on its clinical development activities and reported its financial results for the first quarter ended March 31, 2020.

• Marinus Pharmaceuticals Announces Formation of Scientific Advisory Board

  30 April 2020

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the formation of a Scientific Advisory Board (SAB) with the appointment of six leading experts in clinical neurology and seizure disorders: Jacqueline French, M.D., Lawrence Hirsch, M.D., Aatif Husain, M.D., Michael Rogawski M.D., Ph.D., Eugen Trinka, M.D. and Henrikas Vaitkevicius, M.D.

• Syndax Announces Proposed Public Offering of Common Stock

  29 April 2020

  

  Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it plans to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Syndax also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold in the public offering. All of the shares in the proposed offering are to be sold by Syndax.

• binx health Announces Second FDA 510(k) Clearance of its Molecular Point-of-Care Infectious Disease Platform

  29 April 2020

  

  binx health, a leader in infectious disease testing solutions, announced that it has received a second 510(k) clearance from the U.S. Food and Drug Administration (FDA) in one of the largest markets for infectious disease testing. Today, the Company announces FDA 510(k) clearance to market its sensitive and specific, molecular point-of-care testing platform, the binx io, for the detection of chlamydia (CT) and gonorrhea (NG)—the two most tested-for STIs globally—in male urine specimens. The Company previously announced, in August of 2019, FDA 510(k) clearance of the binx io for use with clinician and self-collected vaginal swab specimens.

• Clearside Biomedical Revises NDA Resubmission Timeline and XIPERE™ Commercial Partnership with Bausch Health

  28 April 2020

  

  Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today an update to the XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) New Drug Application (NDA) resubmission timeline and to its commercialization and development partnership with Bausch Health Companies Inc. (“Bausch Health”) and Bausch + Lomb, its leading global eye health business.

• Syndax Pharmaceuticals Announces Preclinical Profile and Initial Phase 1 Data Demonstrating Clinical Activity of Menin Inhibitor SNDX-5613 in Adults with Relapsed/Refractory Acute Leukemias

  27 April 2020

  

  Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today presents preclinical and initial clinical data for SNDX-5613, the Company's potent, highly selective oral menin inhibitor.

• Clearside Biomedical Appoints Nancy J. Hutson, Ph.D. to its Board of Directors

  22 April 2020

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that  Nancy J. Hutson , Ph.D. has been appointed to the Company's Board of Directors, effective  April 21, 2020.